Oncology

A randomized trial and a cross-sectional analysis have found that remote patient monitoring had a positive impact on people with cancer during the COVID-19 pandemic, while a survey suggests that patients also find the approach favorable.

Preliminary research presented at the 2021 ASCO Annual Meeting suggests that use of a bacterial product might improve response to checkpoint inhibitor therapy in patients with metastatic renal cell carcinoma.

Updated results from the phase 3 KEYNOTE-045 trial show that pembrolizumab monotherapy continues to be associated with improved long-term outcomes relative to chemotherapy in advanced urothelial cancer patients who have progressed on platinum-based chemotherapy.

This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Treatment with immune checkpoint inhibitors may improve the overall survival of people with metastatic small-cell urothelial cancer, suggests a chart review.

The quality of life data from the phase 3 EV-301 study add support for the use of enfortumab vedotin in previously treated patients with advanced urothelial carcinoma.

Results from the phase 2 VIM trial support the use of vinorelbine in patients with malignant pleural mesothelioma whose disease has progressed following platinum-based therapy.